chevron_leftBack
As of 24 April 2025, Suven Life Sciences Ltd. has a market cap of $330.32M USD, ranking #14378 globally and #933 in India. It ranks #1411 in the Healthcare sector, and #345 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$330.32MUSD
28.19B INR
Enterprise Value
$310.22MUSD
26.52B INR
Revenue (TTM)
$887.61KUSD
75.74M INR
EBITDA (TTM)
-$17.8MUSD
-1.52B INR
Net Income (TTM)
-$16.8MUSD
-1.43B INR
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Venkateswarlu Jasti
open_in_new
Employees
141
Founded
1989
Website
suven.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.5% | 1.5% | 3.5% | -0.7% | 5.1% | 22% |
Upcoming Earnings
Earnings Date
Wed, May 28
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SUVEN
Suven Life Sciences Ltd
ISIN: INE495B01038
Shares Out.:
Shares Outstanding:
218.074M1
Shares Float:
61.576M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
130.10 INR | |
|
530239
(SUVEN)
Suven Life Sciences Ltd
ISIN: INE495B01038
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
126.30 INR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Suven Life Sciences Ltd.
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
